Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene therapy rising: Bluebird soars at ASH, Pfizer builds platform

This article was originally published in Scrip

Executive Summary

With the potential to cure debilitating diseases, gene therapy has become a darling of the biotechnology industry. The latest evidence: Bluebird Bio's 8 December after-hours stock market rise by 43.2% to $70 per share on data from four transfusion-free beta-thalassemia patients and Pfizer's investment in a gene therapy platform that includes a hemophilia B collaboration with Spark Therapeutics.

You may also be interested in...



BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications

As updated Phase I/II results for BioMarin's hemophilia A and Spark's hemophilia B gene therapies were presented on May 22, it was revealed that FDA plans to make hemophilia the first gene therapy indication eligible for accelerated approval based on a surrogate endpoint.

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

BMS Makes The Case For A Lasting Hematology Legacy

Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel